Left Atrial Appendage Closure after Ablation for Atrial Fibrillation

Area of Science:

• Cardiology
• Interventional Cardiology
• Medical Devices

Background:

• Oral anticoagulation is standard post-atrial fibrillation ablation for stroke risk.
• Left atrial appendage closure (LAAC) offers a mechanical alternative, but data post-ablation is limited.

Purpose of the Study:

• To compare the safety and efficacy of LAAC versus oral anticoagulation (OAC) in patients undergoing atrial fibrillation ablation.
• To evaluate LAAC as an alternative to OAC for stroke prevention in this population.

Main Methods:

• International randomized trial of 1600 patients with atrial fibrillation and high CHA₂DS₂-VASc scores undergoing catheter ablation.
• Patients were randomized 1:1 to LAAC or OAC.
• Primary safety endpoint: non-procedure-related major or clinically relevant nonmajor bleeding (superiority). Primary efficacy endpoint: composite of death, stroke, or systemic embolism (noninferiority).

Main Results:

• LAAC group (803 patients) showed significantly lower primary safety events (8.5%) vs. OAC group (797 patients, 18.1%; P<0.001).
• LAAC was noninferior to OAC for the primary efficacy endpoint (5.3% vs. 5.8%; P<0.001).
• Complications related to LAAC occurred in 23 patients.

Conclusions:

• Left atrial appendage closure is safer than oral anticoagulation regarding bleeding after atrial fibrillation ablation.
• LAAC is a noninferior alternative to oral anticoagulation for preventing stroke, death, or systemic embolism in patients post-ablation.